Onco Wiki / Indication

Carcinome parathyroïdien · ligne 2 · Pembrolizumab en monothérapie

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.

Source YAML: dossier complet

Notes

STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode- exempted draft content). Reuses REG-PEMBROLIZUMAB-MONO (cross-disease generic pembrolizumab-monotherapy regimen already in the KB) and DRUG-PEMBROLIZUMAB rather than creating a duplicate regimen. No parathyroid-carcinoma-specific pembrolizumab trial exists; evidence is extrapolated from the tissue-agnostic MSI-H/dMMR (KEYNOTE-158/164) and TMB-high FDA approvals for solid tumors generally — see DRUG-PEMBROLIZUMAB.regulatory_status.fda.indications_brief and BIO-TMB-HIGH.interpretation_notes (both already in the KB) for that basket-trial context. `sources` cite the two disease-level NCCN guidelines already attached to DIS-PARATHYROID-CARCINOMA as `position: context` (cross-cutting biomarker-driven-therapy principle) rather than `supports`, because neither guideline directly addresses parathyroid carcinoma pembrolizumab use — no new Source stub was authored for KEYNOTE-158 because it is not explicitly named in the Disease narrative supplied for this task. Given the extreme rarity of parathyroid carcinoma, disease-specific prospective trial data is unlikely to ever exist — this Indication documents the best available (tiss...

Utilisé par

Algorithmes

• ALGO-PARATHYROID-CARCINOMA-1L - ALGO-PARATHYROID-CARCINOMA-1L

Maladie

• DIS-PARATHYROID-CARCINOMA - Carcinome parathyroïdien

Indication

• IND-PARATHYROID-CARCINOMA-2L-CINACALCET - IND-PARATHYROID-CARCINOMA-2L-CINACALCET